Open sharing of clinical trial data has been proposed as a way to address the gap between the production of clinical evidence and the decision-making of physicians. A similar gap was addressed in the software industry by their open-source software movement. Here, we examine how the social and technical principles of the movement can guide the growth of an open-source clinical trial community.
" " HACKERS AS ROLE MODELS Despite the rapid increase in the volume of published biomedical research (1) , physicians of en make decisions without access to the synthesized evidence they need to practice evidence-based medicine (2, 3) . Although improvements in research translation have been made through mandatory clinical trial registration, patient advocacy, and public-private partnerships (4) (5) (6) (7) (8) (9) , the gap between biomedical advances and their incorporation into clinical practice remains a grand challenge for health care (10) .
Hackers-authority-questioning sof ware developers who helped orchestrate the free sof ware movement-successfully addressed a similar gap in the sof ware industry. T is iconoclastic group fundamentally altered the sof ware industry by devising the principles that drive the open-source sof ware movement, countering the economic and cultural motivations that drove the production of closed-source sof ware, disengagement with user needs, and poor interoperability. Similar roadblocks plague the clinical evidence domain. Here, we describe how the opensource sof ware movement can guide growth of an emerging open source ef ort in the clinical trial community ( Fig. 1 ).
FREEDOM OF INFORMATION
T e open-source sof ware movement grew out of the intellectual curiosity of hackers and a fundamental belief that all informa-tion should be free (11) . In this case, "free" meant "libre" (no restrictions) rather than just "gratis" (zero cost). T e so-called four freedoms of open-source sof ware include the freedom to run a program for any purpose, to study how the program works and change it, to redistribute copies, and to distribute modif ed copies (12) .
Success of the open-source sof ware movement is driven by the developers' active engagement with users in the sof ware creation and testing phases, and the rapid f lling of gaps in functionality by a decentralized cadre of developers, a process supported by online communities formed around repositories of code. GitHub, the largest code host in the world, was started in 2008 and has 1.2 million users and hosts 3.5 million repositories. SourceForge is the second largest and most established, with over 326,000 diverse sof ware projects supported by a globally distributed community of 2.7 million developers. Examples of widely used open-source sof ware include the Firefox Web browser, the Apache Web server, and the Android and Symbian operating systems, which are used globally on smart phones.
Open-source communities of en outperform their closed-source counterparts when addressing the needs of users (13), arguably as a direct consequence of the dialogue with users and the interoperability that comes from transparency and developer interaction (14) . Users of open-source sof ware are encouraged to become directly involved in the process by reporting issues and gaps in functionality that they wish to see addressed, even if they are unable to contribute directly to sof ware development.
Individuals and organizations of all sizes participate in open-source sof ware communities with a variety of motivations that range from career development to reputation building. Large companies f nd value in open-source sof ware development as a way to improve the "social contagion" of their products by engaging directly with heavy users (15) . Industry giants prof t by of ering complimentary services (16) and engaging with open-source communities to identify talent and recruit open-source developers to their companies (for an online curriculum vitae service, see http://geekli. st/beta).
FREEING CLINICAL DATA
T e process of translating clinical evidence into practice is slowed by limited sharing of patient-level clinical trial data and bottlenecks in the dissemination of evidence. Industry of en seeks to answer questions in clinical trials that relate to their business agendas rather than answer the questions of most value to clinicians and patients (10, 17) . T ese systemic problems have been attributed to biases that af ect which clinical trials are conducted and which results are published (18) . T e slow dissemination of trustworthy evidence can be obscured by industry marketing delivered through the same channels and the conf icts of interest and low-level evidence that permeate clinical practice guidelines (19) .
Notable successes have come from the expanding of access to deidentif ed patientlevel data. T e Framingham Heart Study resulted in 1872 publications between 1948 and 2007, and when access to genotypic and phenotypic data was opened to a much wider group of researchers, this number increased by 19% to 2223 in just 4 years (20) . In a separate example, the public release of genotypic information associated with an outbreak of Escherichia coli in May 2011 (40 deaths and 3000 cases of infection) led to genomic analyses on four continents (21) . Within a week of public release, the bacterial genome had been assembled and the strain identif ed, and two dozen reports had been f led that provided information on bacterial strain virulence, drug resistance, and phylogenetic lineage.
T e speedy release of the reports on the E. coli outbreak improved clinical practice by indicating which drugs to use (or not use) to treat patients and may have contributed to identif cation of the source of the outbreak by examining the lineage. In another example, a patient-level analysis of a cholesterol treatment was produced collaboratively by researchers who collectively 
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Clinical trial community 35 Patient-level data are rarely shared when producing reviews or meta-analyses Formal and social system for responding to users had conducted 26 clinical trials that included a total of ~170,000 patients (22) . T e protocol for the patient-level meta-analysis was agreed on and published in 1995 before any of the individual trials were completed, making this an early example of broad collaboration and prospective sharing of patient-level clinical trial data. T ere are strong similarities between the processes for collaborative engagement with sof ware source code and patient-level data from clinical trials. T ere are dif erences too, such as the expertise and infrastructure required when producing source code and clinical trial data, privacy concerns associated with patient identif cation, and the sources of funding that underpin the two systems.
EXTRAPOLATING TO PRINCIPLES T e analogy between open-source sof ware development and the synthesis of clinical evidence suggests the following principles for an open-source clinical trial community:
(i) Clinical trialists, other scientif c researchers, and clinicians can access and contribute to a repository of interoperable patient-level data that sits alongside the mandatory registration and provision of summary-level clinical trial results.
(ii) Infrastructure for repositories, data standards, and interaction among clinical trialists must be provided to foster the growth of a decentralized community that mainly aims to rapidly identify and address gaps in clinical evidence.
(iii) Improved dialogue between trialists and physicians, which would allow physicians to routinely ask new questions of the clinical trial community and follow and discuss the aggregated clinical trial data to answer existing questions.
An open-source clinical trial community requires data standards that allow trials to be recorded in a uniform way while retaining the % exibility to represent the variety of protocols and interventions that exist in current clinical trial registries (23) . T e development of data standards can be slow and laborious, but this is an area in which much work has been done (24). Sim and colleagues (25) have led the design of data standards to capture machineinterpretable knowledge bases and the design of a framework for storing summary information with enough detail for searching and aggregating across clinical trials. Other examples of standards and developing communities that support the exchange of clinical trial data include the Study Data Tabulation Model (26) and Open mHealth (27) . By leveraging the most % exible of the data standards, it should be possible to create, store, and aggregate data sets without losing the rigor of the protocols established within individual clinical trials. We envision a set of tools similar to those provided by GitHub or SourceForge, which will allow clinical trial researchers to submit deidentif ed patient-level outcome data alongside the usual metadata expected when registering clinical trials (23) . Each submitted module would represent patient-level outcomes separated by study arms, coupled with information about the patient inclusion criteria and the interventions applied. Modules with equivalent interventions may be combined and compared against alternatives to produce the equivalent of patientlevel meta-analyses. Outcome dif erences between groups of patients who received the same intervention can still be analyzed against dif erences in phenotype, genotype, and setting (combining homogeneous groups and performing subgroup analysis between heterogeneous groups), just as is done today in multicenter trials and metaanalyses. T e ultimate benef t of such an approach would be an increase in the utility of all clinical trials through improved connectivity between, and access to, the data needed for patient-level meta-analyses; such collaborations and analyses may thus permit construction of a richer evidence base for clinical practice guidelines.
Patient-level meta-analyses are rarely performed. Only ~50 patient-level metaanalyses are published each year, compared with the ~17,500 clinical trials registered with ClinicalTrials.gov, and the 75 clinical trials and 11 systematic reviews published each day (1, 23) . T is is despite a long list of advantages that patient-level meta-analyses have over meta-analyses based on trial summary information (28) . T e disadvantage of patient-level meta-analysis is the timeconsuming nature of coordination and data management issues that would be largely resolved by standardizing data storage methods, information reporting standards, and avenues for worldwide collaboration and communication. As a consequence of sharing, it will also be possible to genuinely decouple the collection of data and the analysis for study types ranging from controlled trials of single interventions to more complex studies such as network meta-analyses. Under most open-source licenses, attribution of published syntheses would automatically % ow back to the individuals and groups who contribute data, and it would be possible to extend open-source licenses to include coauthorship privileges.
As is the case for sof ware users in the open-source sof ware movement, the opensource clinical trial community would facilitate the direct participation of physicians who are seeking decision support. As an open-access repository, physicians would have access to the conclusions drawn from large patient-level meta-analyses and f nd trust in the transparency of the analyses and underlying data. Physicians could request answers to new and clinically relevant questions that have not yet been suf ciently addressed by clinical trials (29, 30) . T is could be done in the same way that sof ware features are requested in open-source communities-via an online submission system. As a consequence, a direct dialogue is created between those producing the evidence and the physicians using the evidence in their decisionmaking process in the care of patients.
By creating a platform to improve the way patient-level data are shared and directly engaging the users of clinical evidence in the process, the data developers (clinical and translational scientists) will be better able to provide the evidence that physicians need in their practices. Also, researchers will improve the utility of the evidence they produce by reusing outcome data in subsequent analyses and reducing the bottlenecks associated with data access (31) . T ese enhancements can be expected to improve the utility of clinical trial data through reuse and more appropriate aggregation and synthesis and reduce the burden of waste associated with research data more generally (32) .
CONFRONTING THE CHALLENGES
Technical challenges around building an open-source community for clinical trials include the application of methods to avoid or eliminate the potential for identifying individual patients (33) and implementation of new ways to address data quality standards, which can be low for decentralized contributions (4, 18) . Less onerous challenges include providing the sof ware infrastructure and tools that foster discussion, growth, and dialogue with physicians and tools that aid the self-governance of quality.
Privacy is clearly a concern when providing open access to patient-level data for cases in which deidentif cation cannot be ensured (33) . One solution is to require signed agreements to prevent the release of information that could be used to identify individuals, as is currently done for access to existing longitudinal data sets. An alternative would be to generate statistically identical samples on request, allowing all necessary inferences to be made without compromising privacy.
Perhaps the most important challenge faced by the clinical trial community comes from the currently unbalanced value system in which publish-or-perish mentalities and marketing concerns of en outweigh the value of making ef ective contributions to the support of clinical decision-making. Pharmaceutical companies may have an aversion to providing open access to patient-level data because it may reduce their ability to control the conclusions that are drawn or to avoid dissemination of unfavorable results. In open-source sof ware the incentives for participation are understood, even by large companies (16, 34) , and these values may also be discovered by pharmaceutical companies. Addressing the participation challenge will depend on the choosing or creating of licenses that usefully capture contributions in order to confer recognition for those contributions in publications and by career progression. Sof ware developers routinely use open-source contributions to compete for career advancement.
T ere has been a recent international shif toward requiring open access to all publications that result from publicly funded clinical trials. A further push-at least for trials with nonindustry funding sources-may come from extending the mandate of open-access publication to include open access to patientlevel data for publicly funded clinical trials.
Despite the technical and social challenges, substantial movement toward crowdsourcing and open access to data has already been seen in early-phase drug development (7, 35, 36) , apparently in response to the slowing of approvals that signaled a grand challenge for the f eld (37) . T e domain of clinical data for the practice of evidencebased medicine faces its own grand challenge and requires a similar push to close the gap between what physicians need and the ways in which trials are funded, conducted, and reported. By recognizing the open-source sof ware community as a role model for improvement, the clinical and translational research community can establish principles, standards, and tools that catalyze the growth of a more ef cient and socially responsible clinical trial community.
